Patrick Lucy
Chairman chez DYADIC INTERNATIONAL, INC.
Fortune : 45 381 $ au 31/03/2024
Profil
Patrick K.
Lucy was the founder and had founded Pelican Inc in 2009, where he held the title of Chief Business Officer & Senior Vice President from 2017 to 2020.
He is currently the President, Chief Executive Officer & Director at Lykan Bioscience LLC since 2021, President & Chief Executive Officer at Roslin Cell Therapies Ltd., and Chairman at Dyadic International, Inc. since 2021.
Mr. Lucy's former positions include Director-Business Development at Collaborative BioAlliance Inc & Collaborative Smithfield Corp from 1999 to 2002, Director-Business Development at Dowpharma from 2002 to 2009, and Principal at The Dow Chemical Co. He was also a Principal at Repligen Corp.
from 1991 to 1998 and Manager-Validation & Capital Project at Lonza Biologics Plc from 1996 to 1999.
Mr. Lucy obtained his undergraduate degree from Villanova University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 11/04/2024 | 27 174 ( 0,09% ) | 45 381 $ | 31/03/2024 |
Postes actifs de Patrick Lucy
| Sociétés | Poste | Début |
|---|---|---|
| DYADIC INTERNATIONAL, INC. | Chairman | 28/03/2024 |
Lykan Bioscience LLC
 Lykan Bioscience LLC Pharmaceuticals: MajorHealth Technology Lykan Bioscience LLC provides outsourced end-to-end production and logistics solutions for pharmaceutical and biotech companies focused on cell and gene therapies. The company was founded by Anthony Rotunno and is headquartered in Hopkinton, MA. | Chief Executive Officer | 01/04/2021 |
Roslin Cell Therapies Ltd.
 Roslin Cell Therapies Ltd. BiotechnologyHealth Technology Roslin Cell Therapies Ltd. is a leading contract development and manufacturing services organization focused on advanced cell and gene therapies. The company was established in 2006 and is based in Edinburgh, UK. and has subsidiaries in the United States. Roslin Cell Therapies has a remarkable heritage in the field, having been among the first in the world to produce clinical-grade human pluripotent stem cells and advancing the first CRISPR edited stem cell-based therapy for a major disease to marketing authorization. The British company provides innovative process and analytical development, CGMP clinical and commercial manufacturing for a range of cell types, and CGMP iPSC cell line development, gene editing, and differentiation. With tailored CDMO solutions, Roslin Cell Therapies enables partners to efficiently progress from development to commercialization and deliver life-saving cell and gene therapies worldwide. Peter Alistair Coleman has been the CEO of the company since 2022. | Chief Executive Officer | - |
Anciens postes connus de Patrick Lucy
| Sociétés | Poste | Fin |
|---|---|---|
| PFENEX INC. | Chief Executive Officer | 03/08/2017 |
Dowpharma
 Dowpharma Chemicals: SpecialtyProcess Industries Dowpharma Manufactures and distributes chemical, pharmaceutical, and biopharmaceutical products. It offers nucleic acid medicines, peptides, and ChelaMed radiopharmaceutical products. The company is headquartered in Cambridge, UK. | Corporate Officer/Principal | 01/01/2009 |
Collaborative BioAlliance Inc & Collaborative Smithfield Corp
 Collaborative BioAlliance Inc & Collaborative Smithfield Corp Pharmaceuticals: MajorHealth Technology Part of Dow, Inc., Collaborative BioAlliance Inc & Collaborative Smithfield Corp is an American company that develops and manufactures biopharmaceutical drugs. The private company is based in NY. Collaborative BioAlliance Inc & Collaborative Smithfield was acquired by The Dow Chemical Co., a SUB of Dow, Inc. from Engelhard Long Island, Inc. on November 17, 2000. | Corporate Officer/Principal | 01/01/2002 |
Lonza Biologics Plc
 Lonza Biologics Plc Miscellaneous Commercial ServicesCommercial Services Lonza Biologics Plc manufactures monoclonal antibodies, recombinant proteins and diagnostic monoclonal antibodies. The company was founded in 1897 and is headquartered in Slough, the United Kingdom. | Corporate Officer/Principal | 01/01/1999 |
| REPLIGEN CORPORATION | Corporate Officer/Principal | 01/01/1998 |
Formation de Patrick Lucy
| Villanova University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| REPLIGEN CORPORATION | Health Technology |
| DYADIC INTERNATIONAL, INC. | Health Services |
| Entreprise privées | 7 |
|---|---|
The Dow Chemical Co.
 The Dow Chemical Co. Chemicals: SpecialtyProcess Industries The Dow Chemical Co. engages in the manufacture and distribution of chemicals, plastics, industrial and agricultural products. It serves agriculture, automotive, building and construction, consumer, electronic materials, infrastructure, packaging, product finder and product safety industries. The company was founded by Herbert Henry Dow in 1897 and is headquartered in Midland, MI. | Process Industries |
Lonza Biologics Plc
Lonza Biologics Plc Miscellaneous Commercial ServicesCommercial Services Lonza Biologics Plc manufactures monoclonal antibodies, recombinant proteins and diagnostic monoclonal antibodies. The company was founded in 1897 and is headquartered in Slough, the United Kingdom. | Commercial Services |
Collaborative BioAlliance Inc & Collaborative Smithfield Corp
Collaborative BioAlliance Inc & Collaborative Smithfield Corp Pharmaceuticals: MajorHealth Technology Part of Dow, Inc., Collaborative BioAlliance Inc & Collaborative Smithfield Corp is an American company that develops and manufactures biopharmaceutical drugs. The private company is based in NY. Collaborative BioAlliance Inc & Collaborative Smithfield was acquired by The Dow Chemical Co., a SUB of Dow, Inc. from Engelhard Long Island, Inc. on November 17, 2000. | Health Technology |
Dowpharma
Dowpharma Chemicals: SpecialtyProcess Industries Dowpharma Manufactures and distributes chemical, pharmaceutical, and biopharmaceutical products. It offers nucleic acid medicines, peptides, and ChelaMed radiopharmaceutical products. The company is headquartered in Cambridge, UK. | Process Industries |
Pelican Inc
 Pelican Inc BiotechnologyHealth Technology Pfenex, Inc. is a development and licensing Biotechnology Company, which focuses on leveraging its Pfenex Expression Technology platform for developing and improving protein therapies. Its products include PF708, PF743, PF745, CRM197, PF810, PF753 and PFXX. The company was founded on November 19, 2009 and is headquartered in San Diego, CA. | Health Technology |
Lykan Bioscience LLC
Lykan Bioscience LLC Pharmaceuticals: MajorHealth Technology Lykan Bioscience LLC provides outsourced end-to-end production and logistics solutions for pharmaceutical and biotech companies focused on cell and gene therapies. The company was founded by Anthony Rotunno and is headquartered in Hopkinton, MA. | Health Technology |
Roslin Cell Therapies Ltd.
Roslin Cell Therapies Ltd. BiotechnologyHealth Technology Roslin Cell Therapies Ltd. is a leading contract development and manufacturing services organization focused on advanced cell and gene therapies. The company was established in 2006 and is based in Edinburgh, UK. and has subsidiaries in the United States. Roslin Cell Therapies has a remarkable heritage in the field, having been among the first in the world to produce clinical-grade human pluripotent stem cells and advancing the first CRISPR edited stem cell-based therapy for a major disease to marketing authorization. The British company provides innovative process and analytical development, CGMP clinical and commercial manufacturing for a range of cell types, and CGMP iPSC cell line development, gene editing, and differentiation. With tailored CDMO solutions, Roslin Cell Therapies enables partners to efficiently progress from development to commercialization and deliver life-saving cell and gene therapies worldwide. Peter Alistair Coleman has been the CEO of the company since 2022. | Health Technology |
